U076 From Hesitation to Confidence: Mastering Safe Prescribing in Inflammatory Skin Disorders
DESCRIPTION
With the expansion of oral and injectable therapeutics for the treatment of inflammatory skin disorders, awareness of therapeutic safety and monitoring is paramount to facilitate effective management by dermatologists. This session will focus on essential strategies for safely initiating, and managing therapeutics, including practical protocols for laboratory monitoring, immunizations, identifying early warning signs, and navigating real-world challenges. We will also discuss effective approaches for communicating risk, safety, and expectations with patients to foster shared decision-making and enhance adherence. Cases discussed will include treatment and monitoring of psoriasis, atopic dermatitis, alopecia areata, cutaneous lupus erythematosus, and dermatomyositis. This session will empower attendees to prescribe confidently, monitor efficiently, and respond proactively to complications.
LEARNING OBJECTIVES
Recognize novel oral and biologic therapeutics available for inflammatory dermatologic disorders and associated adverse events
Discuss initiation and monitoring strategies in patients on these treatments to ensure safe prescribing patterns.
DIRECTOR
Neda Shahriari, MD, FAAD
SPEAKER
Mona Shahriari, MD, FAAD
DISCLOSURES
Mona Shahriari, MD, FAAD
AbbVie – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); CoreEvitas, LLC – Advisory Board(Honoraria), Investigator(Fees); Dermavant Sciences – Investigator(Grants/Research Funding), Speaker(Honoraria); Eli Lilly and Company – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker/Faculty Education(Honoraria); Galderma – Advisory Board(Honoraria), Speaker(Honoraria); Incyte Corporation – Advisory Board(Honoraria); Janssen Biotech – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); LEO Pharma, US – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); National Psoriasis Foundation – Speaker/Faculty Education(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Sanofi/Regeneron – Consultant(Honoraria), Speaker(Honoraria); UCB – Consultant(Honoraria), Speaker(Honoraria);
Neda Shahriari, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria); AstraZeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Incyte – Consultant (1099 relationship)(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); UCB – Consultant (1099 relationship)(Honoraria);